A Signaling Nexus for Both Good and Ill, It’s Pathways of Pathogenic and Therapeutic Importance Are Still Being Identified A recent paradigm shift in medicine started with the finding that several ...
Eli Lilly buys Ventyx Biosciences for $1.2B, targeting oral NLRP3 inflammasome inhibitors to expand its immunology pipeline ...
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic lateral sclerosis (“ALS”) This study showed that NLRP3 ...
NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com/), a clinical-stage biotech company developing novel, first-in-class dual ...
Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of morbidity and mortality globally. Obesity, diabetes, and hypertension are highly ...
Atherosclerosis, an inflammatory disease characterized by buildup of cholesterol, lipids, and other substances (plaque) in arteries leading to heart attack and stroke, is accelerated in patients with ...
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains a leading infectious threat to public health worldwide. It is estimated to have infected 2–3 billion people and ...
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains a leading infectious threat to public health worldwide. It is estimated to have infected 2–3 billion people and ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
ZyVersa reports IC 100's potential to inhibit Alzheimer's progression by targeting NLRP3 inflammasomes, enhancing Aβ degradation in preclinical studies. ZyVersa Therapeutics, Inc. announced promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback